Healthcare Resources Use in Patients with Human Immunodeficiency Virus (HIV). Real-World Evidence From Six Italian Local Health Units

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES Farmeconomia-Health Economics and Therapeutic Pathways Pub Date : 2018-07-11 DOI:10.7175/FE.V19I1.1353
V. Perrone, D. Sangiorgi, S. Buda, M. Andretta, S. Borrè, C. Cattaruzzi, G. Gasperini, F. Lena, A. Pisterna, L. Esposti
{"title":"Healthcare Resources Use in Patients with Human Immunodeficiency Virus (HIV). Real-World Evidence From Six Italian Local Health Units","authors":"V. Perrone, D. Sangiorgi, S. Buda, M. Andretta, S. Borrè, C. Cattaruzzi, G. Gasperini, F. Lena, A. Pisterna, L. Esposti","doi":"10.7175/FE.V19I1.1353","DOIUrl":null,"url":null,"abstract":"AIM: The aim of the study was to evaluate healthcare resource use and related costs for the management of people living with Human Immunodeficiency Virus (PLWHIV) with and without comorbidities, and to compare the burden of comorbidities in PLWHIV to the general population.METHODS: An observational retrospective analysis, based on administrative and laboratory databases from 6 Italian Local Health Units (LHUs) was performed. Individuals receiving either an HIV treatment [Antiretroviral therapy (ART) – ATC code: J05A)], or with an HIV positive laboratory test result between January 1st, 2014 and December 31st, 2014 were included. The date of first ART prescription or positive test of HIV was used as the Index Date (ID). Patients enrolled were followed-up for all time available from the ID (follow-up period) and their clinical characteristics were investigated from one year prior to the ID (characterization period). Comorbidities were measured by using the Charlson Comorbidity Index; findings were compared with those of a sample of the general population with the same age and sex distribution (OsMed 2015). Healthcare resource use and related cost was evaluated during the follow-up period.RESULTS: 1,214 patients were included, 837 were PLWHIV without any comorbidities and 377 were PLWHIV with at least one comorbidity. Mean prevalence of prescriptions for treatment of comorbidities was higher in the HIV-infected population than in the Italian general population. The annual healthcare cost of managing HIV patients with comorbidities, was significantly higher than that for patients without comorbidities (€ 10,615 vs. € 8,665, p < 0.001).CONCLUSIONS: Study results showed that 30% of PLWHIV had at least one comorbidity. The cost of managing PLWHIV who have comorbidities was significantly higher than that of managing PLWHIV without comorbidities. Our data confirm that care and treatment services should be adapted to address the specific needs of people living with both HIV and comorbidities.","PeriodicalId":41585,"journal":{"name":"Farmeconomia-Health Economics and Therapeutic Pathways","volume":"44 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2018-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmeconomia-Health Economics and Therapeutic Pathways","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7175/FE.V19I1.1353","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 1

Abstract

AIM: The aim of the study was to evaluate healthcare resource use and related costs for the management of people living with Human Immunodeficiency Virus (PLWHIV) with and without comorbidities, and to compare the burden of comorbidities in PLWHIV to the general population.METHODS: An observational retrospective analysis, based on administrative and laboratory databases from 6 Italian Local Health Units (LHUs) was performed. Individuals receiving either an HIV treatment [Antiretroviral therapy (ART) – ATC code: J05A)], or with an HIV positive laboratory test result between January 1st, 2014 and December 31st, 2014 were included. The date of first ART prescription or positive test of HIV was used as the Index Date (ID). Patients enrolled were followed-up for all time available from the ID (follow-up period) and their clinical characteristics were investigated from one year prior to the ID (characterization period). Comorbidities were measured by using the Charlson Comorbidity Index; findings were compared with those of a sample of the general population with the same age and sex distribution (OsMed 2015). Healthcare resource use and related cost was evaluated during the follow-up period.RESULTS: 1,214 patients were included, 837 were PLWHIV without any comorbidities and 377 were PLWHIV with at least one comorbidity. Mean prevalence of prescriptions for treatment of comorbidities was higher in the HIV-infected population than in the Italian general population. The annual healthcare cost of managing HIV patients with comorbidities, was significantly higher than that for patients without comorbidities (€ 10,615 vs. € 8,665, p < 0.001).CONCLUSIONS: Study results showed that 30% of PLWHIV had at least one comorbidity. The cost of managing PLWHIV who have comorbidities was significantly higher than that of managing PLWHIV without comorbidities. Our data confirm that care and treatment services should be adapted to address the specific needs of people living with both HIV and comorbidities.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人类免疫缺陷病毒(HIV)患者的医疗资源使用。来自六个意大利地方卫生单位的真实证据
目的:本研究的目的是评估有或无合并症的人类免疫缺陷病毒(PLWHIV)患者管理的医疗资源使用和相关费用,并将PLWHIV患者的合并症负担与普通人群进行比较。方法:基于6个意大利地方卫生单位(LHUs)的行政和实验室数据库进行观察性回顾性分析。2014年1月1日至2014年12月31日期间接受艾滋病毒治疗[抗逆转录病毒疗法(ART) - ATC代码:J05A)]或艾滋病毒实验室检测结果呈阳性的个体被纳入研究。第一次ART处方或HIV阳性检测的日期作为索引日期(ID)。入组患者从ID(随访期)开始进行所有时间的随访,并从ID(表征期)前一年开始调查其临床特征。采用Charlson合并症指数测定合并症;研究结果与具有相同年龄和性别分布的普通人群样本的结果进行了比较(OsMed 2015)。在随访期间评估医疗资源使用和相关成本。结果:纳入1214例患者,837例PLWHIV无任何合并症,377例PLWHIV至少有一种合并症。在艾滋病毒感染人群中,治疗合并症的处方平均流行率高于意大利普通人群。管理有合并症的艾滋病毒患者的年度医疗保健费用显著高于无合并症的患者(10,615欧元对8,665欧元,p < 0.001)。结论:研究结果显示,30%的plhiv患者至少有一种合并症。管理有合并症的plwhv的成本明显高于管理无合并症的plwhv。我们的数据证实,护理和治疗服务应适应艾滋病毒感染者和合并症患者的具体需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
6
期刊最新文献
The Importance of the Pharmacoeconomic Analyses in Drug Negotiation. A Farewell Editorial [Measurement-Based Procurement Approach for Biosimilars in Italy: A Position Paper] [Burden of Short Bowel Syndrome in Italy: Direct and Indirect Costs and Quality of Life] Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy [Budget Impact Analysis of the Adjuvanted Quadrivalent Influenza Vaccine in the Elderly in Italy]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1